2Liistro F, Falsini G, Bolognese L. The clinical burden of contrast media- induced nephropathy [ J ]. Ital Heart J,2003,4 (10) :668 - 676.
3Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-inducednephropathy and to impreve long-term outcome in patients undergoing percutaneous coronary intervention[ J]. Am J Car- dio,2008,101 ( 3 ) :279 - 285.
4Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease:a meta-a- nalysis of randomized, controlled trials[ J]. Am J Kidney Dis,2004,43 (1):1 -9.
5Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after pereutaneous coronary intervention [ J]. Circu- lation,2002,105 ( 19 ) :2259 - 2264.
6Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction:the RAPPID study [ J ]. J Am Coll Cardiol,2003,41 (12) :2114 -2118.
7Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose Atorvastatin pretreatrnent to prevent contrast-induced nephropathy in patients with a- cute coronary syndromes undergoing percutaneous coronary intervention ( from the ARMYDA-CIN [ atorvastatin for reduction of myocardial dam- age during angioplasty--contrast-induced nephropathy ] trial [ J ]. Am J Cardiol,2011,108 ( 1 ) : 1 - 7.
9Barrett B J,Parfrey P S.Preventing nephropathy induced bycontrast medium[J].N Engl J Med,2006,354(4):379-386.
10Braunwald E,Antman E M,Beasley J W,et al.ACC/AHA2002 guideline update for the management of patients withunstable angina and non-ST-segment elevation myocardialinfarction-summary article:a report of the American College ofCardiology/American Heart Association task force on practiceguidelines(Committee on the Management of Patients withUnstable Angina)[J].J Am Coll Cardiol,2002,40(7):1366-1374.
